Join us for August! The 2024 Frost & Sullivan New Investment Conference Life Sciences New Investment Summit is now accepting registrations

The life sciences industry is embracing new opportunities with technological breakthroughs, market growth, and international industrial layout. Against this backdrop, the All-Party Summit of the New Investment Summit for Life Sciences will focus on new heights of industry development, delving into the latest trends and developments in the global life sciences field. At the conference, Frost & Sullivan will grandly release"Blue Book on the Current Situation and Trends of China's Biopharmaceuticals Going Global in 2024"It provides valuable market insights and strategic guidance for Chinese biopharmaceutical companies in their global layout.

After experiencing continuous changes from darkness to rebirth, the development of China's biopharmaceutical industry faces both challenges and opportunities. Technological innovation continuously writes new chapters in the industry, providing new approaches for treating complex diseases. At the same time, as Chinese biopharmaceutical companies enter an important stage of high-quality development, many enterprises are "setting sail for overseas markets," pushing innovative drugs and medical technologies into international markets in search of broader development space. In the era of incremental growth, the biopharmaceutical industry is driven by innovation, oriented towards clinical value, and taking the globalization strategy as an opportunity to promote industry development forward.

Amid the upsurge in developing new quality productivity, the medical device industry is leading industrial innovation with technological innovation into a new era of transformation. With measures to strengthen basic research and cutting-edge technology development, the autonomous supply capacity and original innovation capability of underlying technologies and key core technologies are continuously strengthening, driving the medical device industry towards the mid- to high-end of the global value chain, bringing unprecedented development opportunities for the industry. While Chinese medical device companies are embarking on the journey of 'going global' to seek growth, comprehensive cost reduction and efficiency improvement have also become important ways for the medical industry to cope with the unpredictable domestic market. Frost & Sullivan will release these findings at the conference.Blue Book on the Current Situation and Development Trends of the Medical Supply Chain Fine Management (SPD) IndustryThis blue book will comprehensively sort out the current development status, future trends, and market opportunities of the SPD industry.

The Frost & Sullivan Growth, Innovation, Leadership Awards (GILA for short), based on the evaluation mechanism of the Frost & Sullivan Best Practices Awards, are aimed at serving China and global businesses.

The year 2024 marks the 63rd anniversary of Frost & Sullivan's global establishment. Frost & Sullivan China will continue to track and research a large number of successful entrepreneurial and investment and financing cases in high-tech industries and strategic emerging industries within 2024. It will conduct objective and in-depth analysis, comprehensively evaluate the innovation capabilities, business models, founding teams, technical capabilities, and development prospects of the participating enterprises, and jointly select with a professional judging committee.20 outstanding biotech leading enterprisesAnd was grandly presented at the relevant session of the 2024 Frost & Sullivan New Investment Conference.

Participate in the collaboration of 'Blue Book on the Current Situation and Trends of China's Biopharmaceuticals Going Global in 2024'

The 'Blue Book on the Current Situation and Development Trends of the Healthcare Supply Chain (SPD) Industry' authored by Frost & Sullivan is dedicated to a deep analysis of the core dynamics in China's healthcare supply chain sector, comprehensively examining the current development status and future direction of the SPD industry. The blue book aims to provide a comprehensive and in-depth strategic planning for various participants within the industry, including corporate decision-makers, policymakers, and investors. The release of the blue book will enhance market participants' in-depth understanding of the SPD industry, including the industry environment, competitive landscape, and emerging market opportunities. It is hoped that through this platform, all parties within the industry can jointly draw a modern development blueprint for China's healthcare supply chain industry and work together to promote the industry towards higher efficiency and intelligence. In addition, the blue book will also provide a stage for participating enterprises to showcase their technical strength, market strategies, and business advantages, promoting knowledge sharing and best practice exchanges within the industry, and jointly stimulating the innovative vitality and continuous progress of China's SPD industry.

The Life Sciences Practice Group of Frost & Sullivan cordially invites enterprises in the SPD field to participate in the Blue Book, to jointly discuss the development direction and prospects of the SPD industry.

Participate in the collaboration on the 'Blue Book on the Current Situation and Development Trends of the Medical Supply Chain Fine Management (SPD) Industry'